Evidence map›Paper›PMID 40998461›Full record

Observational studyBMJ open respiratory research2025

Assessment of peak inspiratory flow in patients with chronic obstructive pulmonary disease: a multicentre, observational, prospective, real-life study.

Valeria Perugini, Chin Kook Rhee, Ji-Yong Moon, Tiew Pei Yee, Seung Won Ra, Pietro Pirina, Kwang Ha Yoo, Bernardino Alcázar Navarrete, Caroline Gouder, Almadana Pacheco and 9 more

Registry-linked trialAbstract readObservational StudyMulticenter Study
In one paragraph

Observational study in BMJ open respiratory research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT04606394 (Peak Inspiratory Flow), which is not on this map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT04606394 phase4completednot on this map

Peak Inspiratory Flow (PIF) and Dry Powder Inhaler (DPI) Performance in Chronic Obstructive Pulmonary Disease (COPD)

TypeinterventionalSponsorPulmonary Research Institute of Southeast MichiganRan2020 to 2021Enrolled30ConditionsCOPDArmsTrelegy Ellipta 100/62.5/25Mcg Inh 30D, Ventolin 90Mcg/Actuation Inhalation Aerosol
3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

19 authors.

Valeria PeruginiRespiratory Effectiveness Group, Ely, Cambridgeshire, UK valeria@regresearchnetwork.org o.usmani@imperial.ac.uk.ORCID http://orcid.org/0000-0002-9516-4862
Chin Kook RheeCollege of Medicine, Seoul St Mary's Hospital, Catholic University of Korea, Seoul, Korea (the Republic of).
Ji-Yong MoonDivision of Pulmonary and Allergy, Department of Internal Medicine, Konkuk University Medical Center, Konkuk University School of Medicine, Seoul, Korea (the Republic of).
Tiew Pei YeeDepartment of Respiratory and Critical Care Medicine, Singapore General Hospital, Singapore.
Seung Won RaDepartment of Internal Medicine,Ulsan University Hospital, University of Ulsan College of Medicine, Ulsan, Korea (the Republic of).
Pietro PirinaDepartment of Medicine, Surgery and Pharmacy, Università degli Studi di Sassari, Sassari, Italy.
Kwang Ha YooDepartment of Internal Medicine, Konkuk University Medical Center, Konkuk University School of Medicine, Seoul, Korea (the Republic of).
Bernardino Alcázar NavarreteDepartment of Respiratory, IBS-Granada, CIBER de Enfermedades Respiratorias (CIBERES), Hospital Universitario Virgen de las Nieves, Granada, Spain.ORCID http://orcid.org/0000-0003-2356-9366
Caroline GouderDepartment of Respiratory Medicine, Mater Dei Hospital, Msida, Malta.
Almadana PachecoPhysical Medicine and Rehabilitation, Virgen Macarena University Hospital, Sevilla, Spain.
Annie Navarro-RolonDepartment of Pneumology, Fundació Hospital Sant Joan de Déu de Martorell, Barcelona, Spain.
Matevz HarlanderDepartment of Pulmonary Diseases, University Medical Centre Ljubljana, Faculty of Medicine, University of Ljubljana, Ljubljana, Slovenia.
Therese LapperreDepartment of Pulmonary Medicine, University Hospital Antwerp, Edegem. Laboratory of Experimental Medicine and Pediatrics, University of Antwerp, Antwerpen, Belgium.
Sean Chee Hong LohRespiratory and Critical Care Medicine, Changi General Hospital, Singapore.
David FoleDepartment of Neumologia, Torrecardenas University Hospital, Almeria, Spain.
Elsa NavalPneumology Service, Hospital Universitario de La Ribera, Alzira, Spain.
Pedro Jose Romero PalaciosDepartment of Medicine, University of Granada, Granada, Spain.
Marc MiravitllesPneumology Department,Vall d'Hebron Institut de Recerca (VHIR), Vall d'Hebron Barcelona Hospital Campus. CIBER de Enfermedades Respiratorias (CIBERES), Vall d'Hebron University Hospital, Barcelona, Spain.
Omar UsmaniNational Heart and Lung Institute (NHLI), Royal Brompton Hospital (RBH) and St Mary's Hospital London, Imperial College London, London, UK valeria@regresearchnetwork.org o.usmani@imperial.ac.uk.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

introductionPatients with chronic obstructive pulmonary disease (COPD) use dry powder inhalers (DPIs) for disease management. DPI effectiveness relies on the patient's peak inspiratory flow (PIF), which may not always be optimal. We conducted an observational multicentre, prospective, real-life cohort study to determine the prevalence of suboptimal PIF in patients with COPD.

methods415 participants (11%, n=47 women, mean age=70±8.7 years, mean forced expiratory volume in 1 s (predicted %)=48.1%) recruited from 17 international centres had baseline PIF recorded with an In-Check Dial device at three resistance levels: (1) low, (2) high and (3) the participant's maintenance device. We also recorded PIF from participants as they would do at home to verify their proper inhalation technique. Participants underwent spirometry and completed questionnaires (COPD Assessment Test (CAT), Test of Adherence to Inhalers (TAI)-12).

resultsOf the 415 participants, 18% of DPI users (n=75) exhibited suboptimal values of PIF (as typical PIF <than what was required for tested inhalers in the study) when evaluated across DPI resistance groups ranging from low (R1) to high (R5) resistance, compared with 14% of participants (n=60) using devices without resistance (R0). Additionally, 14% of study participants were incapable of producing an optimal PIF or unwilling to do so (27%), impacting medication effectiveness. Participants with suboptimal PIF values had higher mean total CAT score (17.7±7) compared with those with optimal PIF values (12.1±7.6). When assessed globally, 37% (n=56) of participants with suboptimal PIF values did not adhere to treatment, highlighting the need for improved patient education and support.

conclusionSuboptimal PIF is common in COPD, requiring regular assessment and tailored inhalers. TRIAL REGISTRATION NUMBER: NCT04606394. Encepp EUPAS34689.

Indexed as

Dry Powder InhalersInhalationPulmonary Disease, Chronic ObstructiveAdministration, InhalationAgedAged, 80 and overFemaleForced Expiratory VolumeHumansMaleMiddle AgedProspective StudiesSpirometryCOPD epidemiologyInhaler devices

Identifiers

PMID40998461
PMCPMC12481310

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.